论文部分内容阅读
目的:探讨应用法维拉韦治疗的新型冠状病毒肺炎(COVID-19)患者血尿酸升高发生情况及其影响因素。方法:收集2020年6月1日至2021年6月30日在北京地坛医院住院并应用法维拉韦5日或10日方案治疗的COVID-19患者的病历资料进行回顾性分析。以法维拉韦用药结束后血尿酸变化率≥30%为血尿酸升高,据此将患者分为血尿酸升高组与无血尿酸升高组,比较2组患者的临床特征(性别、年龄、体重指数、合并疾病情况、吸烟饮酒情况、COVID-19分型、法维拉韦用药方案、用药前血尿酸和肾功能等),采用logistic多因素回归方法分析法维拉韦相关血尿酸升高的影响因素。结果:纳入分析的患者为179例,男性104例(58.1%),女性75例(41.9%);年龄19~70岁,中位年龄43岁。179例患者法维拉韦治疗后血尿酸水平比治疗前明显升高[(451±119)μmol/L比(332±94)μmol/L,n P<0.001];血尿酸变化率为-57.1%~157.8%,中位血尿酸变化率为38.6%;108例(60.3%)患者血尿酸变化率≥30%。接受法维拉韦5日和10日方案治疗患者血尿酸升高发生率分别为46.8%(36/77)和70.6%(72/102),差异有统计学意义(n P=0.001)。多因素logistic回归分析显示,体重指数24.0~<28.0 kg/mn 2(n OR=3.109,95n %CI:1.209~7.994,n P=0.019)和法维拉韦10日方案(n OR=3.017,95n %CI:1.526~5.964,n P=0.001)是法维拉韦相关血尿酸升高的独立危险因素。n 结论:应用法维拉韦治疗的COVID-19患者超过半数可发生血尿酸升高,超重和法维拉韦10日方案是血尿酸升高的独立危险因素。“,”Objective:To explore the occurrence and influencing factors of serum uric acid elevation in patients with coronavirus disease 2019 (COVID-19) treated with favipiravir.Methods:Medical records of patients with COVID-19 who were hospitalized in Beijing Ditan Hospital between June 1, 2020 and June 30, 2021 and treated with the 5- or 10-day regimen of favipiravir were collected and retrospectively analyzed. After favipiravir withdrawal, if the elevation in serum uric acid was ≥30% of baseline level, it was defined as serum uric acid elevation. Then patients were divided into serum uric acid elevation group and non-serum uric acid elevation group. The clinical characteristics such as gender, age, body mass index, comorbidities, smoking and drinking behavior, COVID-19 grade, favipiravir regimen, and serum uric acid level and renal function before treatment in patients between the 2 groups were compared. Influencing factors of favipiravir-associated serum uric acid elevation was analyzed using multivariate logistic regression method.Results:A total of 179 patients were included in the analysis, including 104 (58.1%) males and 75 (41.9%) females, aged from 19 to 70 years with a median age of 43 years. The level of serum uric acid in 179 patients after favipiravir treatment was significantly higher than before [(451±119) μmol/L n vs. (332±94) μmol/L, n P<0.001]. The change rate of serum uric acid from baseline level ranged from -57.1% to 157.8% with the median of 38.6%. The elevation in serum uric acid of ≥ 30% of baseline level occurred in 108 (60.3%) patients. The incidences of serum uric acid elevation in patients treated with 5-day and 10-day regimens of favipiravir were 46.8% (36/77) and 70.6% (72/102), respectively, and the difference between them was significant (n P=0.001). Multivariate logistic regression analysis showed that body mass index 24.0 to <28.0 kg/m n 2 (n OR=3.109, 95n %CI: 1.209-7.994, n P=0.019) and 10-day regimen of favipiravir (n OR=3.017, 95n %CI: 1.526-5.964, n P=0.001) were independent risk factors for favipiravir-associated serum uric acid elevation.n Conclusions:More than half of COVID-19 patients treated with favipiravir can develop serum uric acid elevation. Overweight and 10-day regimen of favipiravir are independent risk factors for serum uric acid elevation in patients.